Considering the promising results of the multiple ongoing clinical trials of Enzalutamide in TNBC and ongoing trial in ER + BC, targeting AR using Enzalutamide could be a useful second line therapy in a subset of HER2 + breast cancer that fail to respond to trastuzumab or develop trastuzumab resistance. This evidence concerns the gene AR and breast carcinoma.